Intranasal Insulin for Weight Management During Smoking Cessation

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ajna Hamidovic
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• smokers (>10 cig/day) for the past 1 year

• normosmic olfactory function

Exclusion Criteria:

• previous/current use of insulin

• current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder

• current pregnancy (or lactation)

• lifetime history of endocrine disease

• excessive alcohol use (>25 standard units of alcohol/week)

• current use of illicit drugs

• current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent

• local infections, inflammation, structural abnormalities, or other nasal pathology

• current use of any medications administered intranasally, including intranasal steroids